 | • レポートコード：D0GIR-01355 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、122ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、固形腫瘍治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。固形腫瘍治療薬の種類別市場規模（小分子、生物製剤）、用途別市場規模（病院、クリニック、学術・研究機関）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Hoffmann-La Roche、GSK、Johnson & Johnson、Novartis、Eli Lilly、Celgene、Sanofi、BMS、Pfizer、Merck、Boehringer Ingelheim、AbbVie、Boston Biomedical、Biogen、AstraZeneca、Daiichi Sankyo、Bayer ・地域別グローバル市場分析 2015年-2020年 ・固形腫瘍治療薬の北米市場（アメリカ、カナダ、メキシコ） ・固形腫瘍治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・固形腫瘍治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・固形腫瘍治療薬の南米市場（ブラジル、アルゼンチン） ・固形腫瘍治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：小分子、生物製剤 ・用途別分析：病院、クリニック、学術・研究機関 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Drugs for Solid Tumors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Drugs for Solid Tumors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Drugs for Solid Tumors market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for Solid Tumors market has been segmented into:
Small Molecules
Biologics
By Application, Drugs for Solid Tumors has been segmented into:
Hospitals
Clinics
Academic and Research Institutes
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Solid Tumors market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Solid Tumors markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Solid Tumors market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for Solid Tumors market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for Solid Tumors Market Share Analysis
Drugs for Solid Tumors competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Solid Tumors sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Solid Tumors sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for Solid Tumors are:
Hoffmann-La Roche
GSK
Johnson & Johnson
Novartis
Eli Lilly
Celgene
Sanofi
BMS
Pfizer
Merck
Boehringer Ingelheim
AbbVie
Boston Biomedical
Biogen
AstraZeneca
Daiichi Sankyo
Bayer
Table of Contents
1 Drugs for Solid Tumors Market Overview
1.1 Product Overview and Scope of Drugs for Solid Tumors
1.2 Classification of Drugs for Solid Tumors by Type
1.2.1 Global Drugs for Solid Tumors Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Drugs for Solid Tumors Revenue Market Share by Type in 2019
1.2.3 Small Molecules
1.2.4 Biologics
1.3 Global Drugs for Solid Tumors Market by Application
1.3.1 Overview: Global Drugs for Solid Tumors Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic and Research Institutes
1.4 Global Drugs for Solid Tumors Market by Regions
1.4.1 Global Drugs for Solid Tumors Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Drugs for Solid Tumors (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Drugs for Solid Tumors Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Drugs for Solid Tumors Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drugs for Solid Tumors Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Drugs for Solid Tumors Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drugs for Solid Tumors Status and Prospect (2015-2025)
2 Company Profiles
2.1 Hoffmann-La Roche
2.1.1 Hoffmann-La Roche Details
2.1.2 Hoffmann-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Hoffmann-La Roche SWOT Analysis
2.1.4 Hoffmann-La Roche Product and Services
2.1.5 Hoffmann-La Roche Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 GSK SWOT Analysis
2.2.4 GSK Product and Services
2.2.5 GSK Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Eli Lilly SWOT Analysis
2.5.4 Eli Lilly Product and Services
2.5.5 Eli Lilly Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.6 Celgene
2.6.1 Celgene Details
2.6.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Celgene SWOT Analysis
2.6.4 Celgene Product and Services
2.6.5 Celgene Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sanofi SWOT Analysis
2.7.4 Sanofi Product and Services
2.7.5 Sanofi Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.8 BMS
2.8.1 BMS Details
2.8.2 BMS Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 BMS SWOT Analysis
2.8.4 BMS Product and Services
2.8.5 BMS Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Pfizer SWOT Analysis
2.9.4 Pfizer Product and Services
2.9.5 Pfizer Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Merck SWOT Analysis
2.10.4 Merck Product and Services
2.10.5 Merck Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Boehringer Ingelheim SWOT Analysis
2.11.4 Boehringer Ingelheim Product and Services
2.11.5 Boehringer Ingelheim Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.12 AbbVie
2.12.1 AbbVie Details
2.12.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 AbbVie SWOT Analysis
2.12.4 AbbVie Product and Services
2.12.5 AbbVie Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.13 Boston Biomedical
2.13.1 Boston Biomedical Details
2.13.2 Boston Biomedical Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Boston Biomedical SWOT Analysis
2.13.4 Boston Biomedical Product and Services
2.13.5 Boston Biomedical Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.14 Biogen
2.14.1 Biogen Details
2.14.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Biogen SWOT Analysis
2.14.4 Biogen Product and Services
2.14.5 Biogen Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.15 AstraZeneca
2.15.1 AstraZeneca Details
2.15.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 AstraZeneca SWOT Analysis
2.15.4 AstraZeneca Product and Services
2.15.5 AstraZeneca Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.16 Daiichi Sankyo
2.16.1 Daiichi Sankyo Details
2.16.2 Daiichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Daiichi Sankyo SWOT Analysis
2.16.4 Daiichi Sankyo Product and Services
2.16.5 Daiichi Sankyo Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
2.17 Bayer
2.17.1 Bayer Details
2.17.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Bayer SWOT Analysis
2.17.4 Bayer Product and Services
2.17.5 Bayer Drugs for Solid Tumors Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Drugs for Solid Tumors Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Drugs for Solid Tumors Players Market Share
3.2.2 Top 10 Drugs for Solid Tumors Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Drugs for Solid Tumors Revenue and Market Share by Regions
4.2 North America Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
4.3 Europe Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
4.5 South America Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
5 North America Drugs for Solid Tumors Revenue by Countries
5.1 North America Drugs for Solid Tumors Revenue by Countries (2015-2020)
5.2 USA Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
5.3 Canada Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
5.4 Mexico Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
6 Europe Drugs for Solid Tumors Revenue by Countries
6.1 Europe Drugs for Solid Tumors Revenue by Countries (2015-2020)
6.2 Germany Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
6.3 UK Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
6.4 France Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
6.5 Russia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
6.6 Italy Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Drugs for Solid Tumors Revenue by Countries
7.1 Asia-Pacific Drugs for Solid Tumors Revenue by Countries (2015-2020)
7.2 China Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
7.3 Japan Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
7.4 Korea Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
7.5 India Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
8 South America Drugs for Solid Tumors Revenue by Countries
8.1 South America Drugs for Solid Tumors Revenue by Countries (2015-2020)
8.2 Brazil Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
8.3 Argentina Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Drugs for Solid Tumors by Countries
9.1 Middle East & Africa Drugs for Solid Tumors Revenue by Countries (2015-2020)
9.2 Saudi Arabia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
9.3 UAE Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
9.4 Egypt Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
9.5 South Africa Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Drugs for Solid Tumors Revenue and Market Share by Type (2015-2020)
10.2 Global Drugs for Solid Tumors Market Forecast by Type (2019-2024)
10.3 Small Molecules Revenue Growth Rate (2015-2025)
10.4 Biologics Revenue Growth Rate (2015-2025)
11 Global Drugs for Solid Tumors Market Segment by Application
11.1 Global Drugs for Solid Tumors Revenue Market Share by Application (2015-2020)
11.2 Drugs for Solid Tumors Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Academic and Research Institutes Revenue Growth (2015-2020)
12 Global Drugs for Solid Tumors Market Size Forecast (2021-2025)
12.1 Global Drugs for Solid Tumors Market Size Forecast (2021-2025)
12.2 Global Drugs for Solid Tumors Market Forecast by Regions (2021-2025)
12.3 North America Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
12.4 Europe Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
12.6 South America Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Drugs for Solid Tumors Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Solid Tumors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Solid Tumors Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Drugs for Solid Tumors Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Hoffmann-La Roche Corporate Information, Location and Competitors
Table 6. Hoffmann-La Roche Drugs for Solid Tumors Major Business
Table 7. Hoffmann-La Roche Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 8. Hoffmann-La Roche SWOT Analysis
Table 9. Hoffmann-La Roche Drugs for Solid Tumors Product and Solutions
Table 10. Hoffmann-La Roche Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. GSK Corporate Information, Location and Competitors
Table 12. GSK Drugs for Solid Tumors Major Business
Table 13. GSK Drugs for Solid Tumors Total Revenue (USD Million) (2018-2019)
Table 14. GSK SWOT Analysis
Table 15. GSK Drugs for Solid Tumors Product and Solutions
Table 16. GSK Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Johnson & Johnson Corporate Information, Location and Competitors
Table 18. Johnson & Johnson Drugs for Solid Tumors Major Business
Table 19. Johnson & Johnson Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 20. Johnson & Johnson SWOT Analysis
Table 21. Johnson & Johnson Drugs for Solid Tumors Product and Solutions
Table 22. Johnson & Johnson Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Novartis Corporate Information, Location and Competitors
Table 24. Novartis Drugs for Solid Tumors Major Business
Table 25. Novartis Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 26. Novartis SWOT Analysis
Table 27. Novartis Drugs for Solid Tumors Product and Solutions
Table 28. Novartis Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Eli Lilly Corporate Information, Location and Competitors
Table 30. Eli Lilly Drugs for Solid Tumors Major Business
Table 31. Eli Lilly Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 32. Eli Lilly SWOT Analysis
Table 33. Eli Lilly Drugs for Solid Tumors Product and Solutions
Table 34. Eli Lilly Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Celgene Corporate Information, Location and Competitors
Table 36. Celgene Drugs for Solid Tumors Major Business
Table 37. Celgene Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 38. Celgene SWOT Analysis
Table 39. Celgene Drugs for Solid Tumors Product and Solutions
Table 40. Celgene Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Sanofi Corporate Information, Location and Competitors
Table 42. Sanofi Drugs for Solid Tumors Major Business
Table 43. Sanofi Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 44. Sanofi SWOT Analysis
Table 45. Sanofi Drugs for Solid Tumors Product and Solutions
Table 46. Sanofi Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. BMS Corporate Information, Location and Competitors
Table 48. BMS Drugs for Solid Tumors Major Business
Table 49. BMS Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 50. BMS SWOT Analysis
Table 51. BMS Drugs for Solid Tumors Product and Solutions
Table 52. BMS Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Pfizer Corporate Information, Location and Competitors
Table 54. Pfizer Drugs for Solid Tumors Major Business
Table 55. Pfizer Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 56. Pfizer SWOT Analysis
Table 57. Pfizer Drugs for Solid Tumors Product and Solutions
Table 58. Pfizer Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Merck Corporate Information, Location and Competitors
Table 60. Merck Drugs for Solid Tumors Major Business
Table 61. Merck Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 62. Merck SWOT Analysis
Table 63. Merck Drugs for Solid Tumors Product and Solutions
Table 64. Merck Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 66. Boehringer Ingelheim Drugs for Solid Tumors Major Business
Table 67. Boehringer Ingelheim Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 68. Boehringer Ingelheim SWOT Analysis
Table 69. Boehringer Ingelheim Drugs for Solid Tumors Product and Solutions
Table 70. Boehringer Ingelheim Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. AbbVie Corporate Information, Location and Competitors
Table 72. AbbVie Drugs for Solid Tumors Major Business
Table 73. AbbVie Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 74. AbbVie SWOT Analysis
Table 75. AbbVie Drugs for Solid Tumors Product and Solutions
Table 76. AbbVie Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Boston Biomedical Corporate Information, Location and Competitors
Table 78. Boston Biomedical Drugs for Solid Tumors Major Business
Table 79. Boston Biomedical Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 80. Boston Biomedical SWOT Analysis
Table 81. Boston Biomedical Drugs for Solid Tumors Product and Solutions
Table 82. Boston Biomedical Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Biogen Corporate Information, Location and Competitors
Table 84. Biogen Drugs for Solid Tumors Major Business
Table 85. Biogen Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 86. Biogen SWOT Analysis
Table 87. Biogen Drugs for Solid Tumors Product and Solutions
Table 88. Biogen Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. AstraZeneca Corporate Information, Location and Competitors
Table 90. AstraZeneca Drugs for Solid Tumors Major Business
Table 91. AstraZeneca Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 92. AstraZeneca SWOT Analysis
Table 93. AstraZeneca Drugs for Solid Tumors Product and Solutions
Table 94. AstraZeneca Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Daiichi Sankyo Corporate Information, Location and Competitors
Table 96. Daiichi Sankyo Drugs for Solid Tumors Major Business
Table 97. Daiichi Sankyo Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 98. Daiichi Sankyo SWOT Analysis
Table 99. Daiichi Sankyo Drugs for Solid Tumors Product and Solutions
Table 100. Daiichi Sankyo Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Bayer Corporate Information, Location and Competitors
Table 102. Bayer Drugs for Solid Tumors Major Business
Table 103. Bayer Drugs for Solid Tumors Total Revenue (USD Million) (2017-2018)
Table 104. Bayer SWOT Analysis
Table 105. Bayer Drugs for Solid Tumors Product and Solutions
Table 106. Bayer Drugs for Solid Tumors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Global Drugs for Solid Tumors Revenue (Million USD) by Players (2015-2020)
Table 108. Global Drugs for Solid Tumors Revenue Share by Players (2015-2020)
Table 109. Global Drugs for Solid Tumors Revenue (Million USD) by Regions (2015-2020)
Table 110. Global Drugs for Solid Tumors Revenue Market Share by Regions (2015-2020)
Table 111. North America Drugs for Solid Tumors Revenue by Countries (2015-2020)
Table 112. North America Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Table 113. Europe Drugs for Solid Tumors Revenue (Million USD) by Countries (2015-2020)
Table 114. Asia-Pacific Drugs for Solid Tumors Revenue (Million USD) by Countries (2015-2020)
Table 115. South America Drugs for Solid Tumors Revenue by Countries (2015-2020)
Table 116. South America Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Table 117. Middle East and Africa Drugs for Solid Tumors Revenue (Million USD) by Countries (2015-2020)
Table 118. Middle East and Africa Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Table 119. Global Drugs for Solid Tumors Revenue (Million USD) by Type (2015-2020)
Table 120. Global Drugs for Solid Tumors Revenue Share by Type (2015-2020)
Table 121. Global Drugs for Solid Tumors Revenue Forecast by Type (2021-2025)
Table 122. Global Drugs for Solid Tumors Revenue by Application (2015-2020)
Table 123. Global Drugs for Solid Tumors Revenue Share by Application (2015-2020)
Table 124. Global Drugs for Solid Tumors Revenue Forecast by Application (2021-2025)
Table 125. Global Drugs for Solid Tumors Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Drugs for Solid Tumors Picture
Figure 2. Global Drugs for Solid Tumors Revenue Market Share by Type in 2019
Figure 3. Small Molecules Picture
Figure 4. Biologics Picture
Figure 5. Drugs for Solid Tumors Revenue Market Share by Application in 2019
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Academic and Research Institutes Picture
Figure 9. Global Drugs for Solid Tumors Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Drugs for Solid Tumors Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Drugs for Solid Tumors Revenue Market Share in 2019
Figure 18. Global Top 10 Players Drugs for Solid Tumors Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Drugs for Solid Tumors Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Drugs for Solid Tumors Revenue Market Share by Regions (2015-2020)
Figure 22. Global Drugs for Solid Tumors Revenue Market Share by Regions in 2018
Figure 23. North America Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 24. Europe Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 26. South America Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 28. North America Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Figure 29. North America Drugs for Solid Tumors Revenue Market Share by Countries in 2019
Figure 30. USA Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 31. Canada Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 33. Europe Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Drugs for Solid Tumors Revenue Market Share by Countries in 2019
Figure 35. Germany Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 36. UK Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 37. France Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 38. Russia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 39. Italy Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Drugs for Solid Tumors Revenue Market Share by Countries in 2019
Figure 42. China Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 43. Japan Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 44. Korea Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 45. India Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 47. South America Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Figure 48. South America Drugs for Solid Tumors Revenue Market Share by Countries in 2019
Figure 49. Brazil Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Drugs for Solid Tumors Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Drugs for Solid Tumors Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 54. UAE Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Drugs for Solid Tumors Revenue and Growth Rate (2015-2020)
Figure 57. Global Drugs for Solid Tumors Revenue Share by Type (2015-2020)
Figure 58. Global Drugs for Solid Tumors Revenue Share by Type in 2019
Figure 59. Global Drugs for Solid Tumors Market Share Forecast by Type (2021-2025)
Figure 60. Global Small Molecules Revenue Growth Rate (2015-2020)
Figure 61. Global Biologics Revenue Growth Rate (2015-2020)
Figure 62. Global Drugs for Solid Tumors Revenue Share by Application (2015-2020)
Figure 63. Global Drugs for Solid Tumors Revenue Share by Application in 2019
Figure 64. Global Drugs for Solid Tumors Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 66. Global Clinics Revenue Growth Rate (2015-2020)
Figure 67. Global Academic and Research Institutes Revenue Growth Rate (2015-2020)
Figure 68. Global Drugs for Solid Tumors Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Drugs for Solid Tumors Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Drugs for Solid Tumors Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
Figure 72. Europe Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
Figure 74. South America Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Drugs for Solid Tumors Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
固形腫瘍薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Solid Tumors Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Solid Tumors Drugs market …- 消化管間質腫瘍（GIST）治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Gastrointestinal Stromal Tumors (GISTs) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.…
- OTC外用薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global OTC Topical Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The OTC Topical Drugs market re…
- 泌尿生殖器薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Genitourinary Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genitourinary Drugs marke…
- 先端巨大症・巨人症治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Acromegaly and Gigantism Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Acromegaly and…